1-3 of 3
Chen Bai
Close
Sort by
Journal Articles

ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML

James Palacino, Pedro Lee, Hangyeol Jeong, Yeonjoon Kim, Yoojin Song, Uttapol Permpoon, Wesley Wong, Chen Bai, Nathan Fishkin, Khuloud Takrouri, Eunjin Yu, Yong Yi, Anna Skaletskaya, Ki-Hwan Chang, Min-Soo Kim, Da-Yeong Kim, Dong-Ki Choi, Peter U Park
Journal: Blood
Blood (2022) 140 (Supplement 1): 3061–3062.
https://doi.org/10.1182/blood-2022-168936
Published: 2022
Journal Articles

IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models

Sharlene Adams, PhD, Alan Wilhelm, Lauren Harvey, MS, Chen Bai, Nicholas Yoder, PhD, Yelena Kovtun, PhD, Thomas Chittenden, PhD, Jan Pinkas, PhD
Journal: Blood
Blood (2016) 128 (22): 2832.
https://doi.org/10.1182/blood.V128.22.2832.2832
Published: 2016
Journal Articles

A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells

Yelena Kovtun, PhD, Gregory Jones, Charlene Audette, Lauren Harvey, MS, Baudouin Gerard, PhD, Alan Wilhelm, Chen Bai, Sharlene Adams, PhD, Victor S Goldmacher, PhD, Ravi Chari, PhD, Thomas Chittenden, PhD
Journal: Blood
Blood (2016) 128 (22): 768.
https://doi.org/10.1182/blood.V128.22.768.768
Published: 2016